Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) was the target of a large decrease in short interest in the month of December. As of December 31st, there was short interest totalling 1,930,639 shares, a decrease of 11.1% from the December 14th total of 2,172,039 shares. Based on an average daily volume of 667,184 shares, the days-to-cover ratio is currently 2.9 days. Currently, 1.7% of the shares of the company are sold short.

Shares of NYSEAMERICAN ATNM opened at $0.44 on Friday. Actinium Pharmaceuticals has a 1 year low of $0.33 and a 1 year high of $0.87.

A number of hedge funds and other institutional investors have recently modified their holdings of ATNM. Renaissance Technologies LLC boosted its stake in Actinium Pharmaceuticals by 1,269.5% during the 2nd quarter. Renaissance Technologies LLC now owns 387,500 shares of the biotechnology company’s stock valued at $248,000 after purchasing an additional 359,205 shares in the last quarter. Essex Investment Management Co. LLC bought a new position in Actinium Pharmaceuticals during the 3rd quarter valued at $816,000. PNC Financial Services Group Inc. bought a new position in Actinium Pharmaceuticals during the 3rd quarter valued at $617,000. Virtu Financial LLC boosted its stake in Actinium Pharmaceuticals by 103.1% during the 3rd quarter. Virtu Financial LLC now owns 195,623 shares of the biotechnology company’s stock valued at $146,000 after purchasing an additional 99,318 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Actinium Pharmaceuticals by 6.4% during the 3rd quarter. Vanguard Group Inc. now owns 2,575,754 shares of the biotechnology company’s stock valued at $1,909,000 after purchasing an additional 154,403 shares in the last quarter.

ATNM has been the topic of several analyst reports. Zacks Investment Research cut Actinium Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, December 3rd. Roth Capital set a $6.00 target price on Actinium Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, December 4th. Maxim Group set a $3.00 target price on Actinium Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, December 3rd. Finally, Oppenheimer set a $5.00 target price on Actinium Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, November 28th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Actinium Pharmaceuticals presently has an average rating of “Buy” and an average price target of $3.55.

TRADEMARK VIOLATION NOTICE: “Actinium Pharmaceuticals Inc (ATNM) Short Interest Update” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://theolympiareport.com/2019/01/13/actinium-pharmaceuticals-inc-atnm-short-interest-update.html.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.

Read More: What is Cost of Capital?

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.